Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Shanghai MicroPort Endovascular MedTech Co., Ltd.

Capitalization 12.97B 1.89B 1.64B 1.48B 1.41B 2.57B 174B 2.66B 17.62B 7B 83.28B 7.08B 6.93B 301B P/E ratio 2025
19.7x
P/E ratio 2026 * 22.9x
Enterprise value 10.1B 1.47B 1.28B 1.15B 1.1B 2B 136B 2.07B 13.72B 5.45B 64.85B 5.52B 5.4B 234B EV / Sales 2025
8.21x
EV / Sales 2026 * 6.37x
Free-Float
59.01%
Yield 2025 *
2.12%
Yield 2026 * 2.11%
02-27 Microport Scientific logs FY net profit attributable for Shanghai MicroPort Endovascular MedTech RMB563.2 mln RE
02-27 Shanghai MicroPort Endovascular MedTech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
29/10/25 Microport Scientific updates on 9-month results of Shanghai Microport Endovascular Medtech RE
29/10/25 Shanghai MicroPort Endovascular MedTech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
28/10/25 Tranche Update on Shanghai MicroPort Endovascular MedTech Co., Ltd.'s Equity Buyback Plan announced on October 29, 2024. CI
26/10/25 Shanghai MicroPort Endovascular MedTech Co., Ltd.'s Equity Buyback announced on October 29, 2024, has closed with 1,333,943 shares, representing 1.09% for CNY 140.1 million. CI
10/10/25 Tranche Update on Shanghai MicroPort Endovascular MedTech Co., Ltd.'s Equity Buyback Plan announced on October 29, 2024. CI
26/08/25 Microport Scientific says HY revenue of Shanghai MicroPort Endovascular MedTech RMB714.4 mln RE
26/08/25 Shanghai MicroPort Endovascular MedTech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
15/07/25 MicroPort Scientific Flags H1 Profit, Revenue Decline in MicroPort Endovascular Medtech; Shares Fall 1% MT
14/07/25 Shanghai Microport Endovascular Medtech Co., Ltd. Provides Earnings Guidance for the Half Year Ended 30 June 2025 CI
14/07/25 MicroPort Endovascular MedTech sees H1 net profit down 10.5-24.8% Y/Y RE
29/04/25 Shanghai MicroPort Endovascular MedTech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day-2.82%
1 week-1.20%
Current month+5.67%
1 month+9.22%
3 months+17.41%
6 months-1.32%
Current year+17.01%
1 week 102.25
Extreme 102.25
112.95
1 month 96.58
Extreme 96.58
116
Current year 91.66
Extreme 91.66
116
1 year 81.81
Extreme 81.81
124.3
3 years 78.62
Extreme 78.62
141.14
5 years 78.62
Extreme 78.62
322.15
10 years 67.79
Extreme 67.7852
322.15
Manager TitleAgeSince
Chief Executive Officer 45 14/07/2021
Director of Finance/CFO 46 27/10/2021
Chief Tech/Sci/R&D Officer 49 13/11/2025
Director TitleAgeSince
Chairman 51 30/12/2025
Director/Board Member 49 13/11/2025
Director/Board Member 40 29/03/2022
Change 5d. change 1-year change 3-years change Capi.($)
-2.82%-1.20%+15.85%-16.16% 1.94B
+0.07%-7.05%-6.82%+27.06% 129B
+0.38%-3.04%+14.06%+5.33% 14.08B
+0.31%+2.32%-26.37%-62.96% 6.22B
-0.51%-9.06%+1.42%+116.51% 5.68B
+1.01%-0.75%+37.75%+13.58% 2.64B
+0.52%+0.64%-12.74%-24.06% 2.02B
-1.41%-8.04%-63.53%-75.30% 1.67B
-1.60%-6.55%-36.04%-57.27% 1.34B
Average -0.47%-3.70%-8.49%-8.14% 18.29B
Weighted average by Cap. +0.04%-7.90%-5.39%+21.81%

Financials

2025 2026 *
Net sales 1.54B 224M 194M 176M 168M 305M 20.66B 315M 2.09B 829M 9.87B 840M 822M 35.63B 1.68B 244M 212M 191M 183M 333M 22.54B 344M 2.28B 905M 10.77B 916M 896M 38.87B
Net income 631M 91.92M 79.74M 72.1M 68.84M 125M 8.49B 130M 858M 341M 4.05B 345M 338M 14.64B 712M 104M 89.94M 81.32M 77.64M 141M 9.57B 146M 968M 384M 4.57B 389M 381M 16.51B
Net Debt -2.87B -418M -362M -328M -313M -569M -38.58B -589M -3.9B -1.55B -18.43B -1.57B -1.53B -66.53B -2.29B -333M -289M -261M -249M -454M -30.75B -470M -3.11B -1.23B -14.69B -1.25B -1.22B -53.03B
Logo Shanghai MicroPort Endovascular MedTech Co., Ltd.
Shanghai MicroPort Endovascular MedTech Group Co Ltd, formerly Shanghai MicroPort Endovascular MedTech Co Ltd, is a China-based company principally engaged in the research and development, production and sales of aortic and peripheral vascular interventional medical devices. The Company's main products include the aortic stent graft system for aortic minimally invasive interventional procedures, the intraoperative stent system for open surgery, as well as the peripheral vascular stent system and peripheral balloon dilatation catheters for the treatment of peripheral vascular diseases. The Company mainly distributes its products to the domestic market.
Employees
826
Date Price Change Volume
12/03/26 107.25 ¥ -2.82% 2,364,310
12/03/26 110.36 ¥ -1.11% 1,948,940
11/03/26 111.60 ¥ +1.50% 3,108,871
10/03/26 109.95 ¥ +5.41% 3,256,315
09/03/26 104.31 ¥ -2.86% 3,280,048
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
110.36CNY
Average target price
129.02CNY
Spread / Average Target
+16.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688016 Stock
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW